Comparação de custos de um edifício residencial executado em alvenaria estrutural e em concreto armado

Artigo submetido ao Curso de Engenharia Civil da UNESC - como requisito parcial para obtenção do Título de Engenheiro Civil.O aumento da concorrência no setor da construção civil tem levado construtoras a estudar novas possibilidades de construir sem perder a qualidade, e que apresentem maior economia para aumentar a sua competitividade no mercado. Para aumentar estas possibilidades muitos sistemas construtivos têm surgido, entretanto existem sistemas construtivos como a alvenaria estrutural de blocos de concreto que são sistemas em que se tem domínio sobre o conhecimento técnico, e muitas vezes não são empregados pelo fato de não se ter conhecimento econômico sobre estes sistemas. O objetivo deste trabalho é comparar economicamente a alvenaria estrutural de blocos de concreto com o sistema convencional e concluir qual sistema construtivo apresenta maior economia para o edifício em estudo. Para isso foi elaborado o projeto estrutural do edifício, o projeto de modulação e paginação da alvenaria estrutural e o dimensionamento dos blocos, o que deu subsídios para o levantamento de materiais e de mão de obra dos subsistemas que representam a maior parcela do custo global da obra. Os itens avaliados neste trabalho são a variação de custos do concreto, do aço, da forma, da alvenaria, do revestimento e da mão de obra para executar a alvenaria, a estrutura e o revestimento. Com a realização do estudo observou-se que o valor dos materiais utilizados na alvenaria em alvenaria estrutural foi aumentado em 126% devido ao valor dos blocos de concreto ser superior ao dos tijolos cerâmicos, mas como todos os outros itens estudados levaram a uma redução de custos houve uma economia final de 12% utilizando a alvenaria estrutural

Conference: Reparations in the Inter-American System: A Comparative Approach Conference

This publication will enhance the understanding of what we call the law of reparations, developed in the Inter-American Court and Commission of Human Rights. Reparations have a special meaning for the victims of human rights violations and, in particular, the victims of mass and gross violations that took place in this hemisphere during the twentieth century. For those victims and their family members, reestablishing the rights as if no violation had occurred is not possible. Accordingly, to them, avoiding the repetition of those violations in the future is of paramount importance. In achieving that goal, what the victims want is the investigation and punishment of those who appear guilty as an essential component of the law of compensation. Material and moral damages, symbolic measures of redress, as well as legislative changes when needed are also crucially important. The inter-American system’s supervisory organs, within the limits of their jurisdiction, and in particular through the interpretation of Article 63 of the American Convention, have creatively developed the law of reparations within the Americas. As a result of the decisions from the supervisory organs, what has emerged is perhaps the most comprehensive legal regime on reparations developed in the human rights field in international law. This contains edited versions of speeches delivered at the conference

Tomo lo que encuentro : 19 versiones de Virus

“No hay que juzgar a un producto argentino por lo que le falta con respecto a uno americano o europeo... La crítica suele ser más permisiva con las producciones extranjeras que con las locales... No quiero que tengamos una fama tan grande que nos impida la libertad de seguir haciendo lo que querramos”. Tres conceptos de Federico Moura en el último reportaje radial que le hice (y que se le hizo), que bastarían para mostrar a alguien atento a lo que pasaba y que tenía las palabras para dar cuenta de ese registro. Esto está presente en toda la obra de Virus. Una producción que siempre fue creciendo en calidad, en forma y contenido. Este CD es el mejor testimonio de su vigencia. Que tantos solistas y grupos platenses, talentosos y apasionados, hayan tenido deseos de hacer su versión de temas de Virus, es el reconocimiento más pleno de una obra genuina, que despierta amor y respeto. Y claro que Federico está. Si no cómo sabríamos que falta. Tom Lupo Contenido: 1 - Sergio Pángaro: "Tomo lo que encuentro" 2 - Míster América: "Dame una señal" 3 - Ex: "El banquete" 4 - Cine Continuado: "Wadu-wadu" 5 - Ahora: "Sin disfraz" 6 - Las Canoplas: "En mi garage" 7 - Federico Kempff: "Desesperado secuencia uno" 8 - Alfredo Calvelo: "Loco coco" 9 - Traviatabosnialafortina: "Juegos postergados" 10 - Estelares: "Pronta entrega" 11 - Falso Primer Ministro: "Danza narcótica" 12 - NerdKids: "Me puedo programar" 13 - Plupart: "Se sarpo" 14 - Francisco Bochatón: "Imágenes paganas" 15 - El César: "El 146" 16 - Los Hermanitos Kaiser y su Increíble Organito que Toca Solo: "Juegos incompletos" 17 - La Secta: "Mirada speed" 18 - Norma: "Densa realidad" 19 - Juan Pablo Bochatón: "Tomo lo que encuentro"Radio Universidad Nacional de La Plat

Exercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy:SEQUOIA-HCM Baseline Characteristics and Study Design

Patients with obstructive hypertrophic cardiomyopathy (oHCM) have increased risk of arrhythmia, stroke, heart failure, and sudden death. Contemporary management of oHCM has decreased annual hospitalization and mortality rates, yet patients have worsening health-related quality of life due to impaired exercise capacity and persistent residual symptoms. Here we consider the design of clinical trials evaluating potential oHCM therapies in the context of SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM). This large, phase 3 trial is now fully enrolled (N = 282). Baseline characteristics reflect an ethnically diverse population with characteristics typical of patients encountered clinically with substantial functional and symptom burden. The study will assess the effect of aficamten vs placebo, in addition to standard-of-care medications, on functional capacity and symptoms over 24 weeks. Future clinical trials could model the approach in SEQUOIA-HCM to evaluate the effect of potential therapies on the burden of oHCM. (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM [SEQUOIA-HCM]; NCT05186818).</p

Tomo lo que encuentro : 19 versiones de Virus

“No hay que juzgar a un producto argentino por lo que le falta con respecto a uno americano o europeo... La crítica suele ser más permisiva con las producciones extranjeras que con las locales... No quiero que tengamos una fama tan grande que nos impida la libertad de seguir haciendo lo que querramos”. Tres conceptos de Federico Moura en el último reportaje radial que le hice (y que se le hizo), que bastarían para mostrar a alguien atento a lo que pasaba y que tenía las palabras para dar cuenta de ese registro. Esto está presente en toda la obra de Virus. Una producción que siempre fue creciendo en calidad, en forma y contenido. Este CD es el mejor testimonio de su vigencia. Que tantos solistas y grupos platenses, talentosos y apasionados, hayan tenido deseos de hacer su versión de temas de Virus, es el reconocimiento más pleno de una obra genuina, que despierta amor y respeto. Y claro que Federico está. Si no cómo sabríamos que falta. Tom Lupo Contenido: 1 - Sergio Pángaro: "Tomo lo que encuentro" 2 - Míster América: "Dame una señal" 3 - Ex: "El banquete" 4 - Cine Continuado: "Wadu-wadu" 5 - Ahora: "Sin disfraz" 6 - Las Canoplas: "En mi garage" 7 - Federico Kempff: "Desesperado secuencia uno" 8 - Alfredo Calvelo: "Loco coco" 9 - Traviatabosnialafortina: "Juegos postergados" 10 - Estelares: "Pronta entrega" 11 - Falso Primer Ministro: "Danza narcótica" 12 - NerdKids: "Me puedo programar" 13 - Plupart: "Se sarpo" 14 - Francisco Bochatón: "Imágenes paganas" 15 - El César: "El 146" 16 - Los Hermanitos Kaiser y su Increíble Organito que Toca Solo: "Juegos incompletos" 17 - La Secta: "Mirada speed" 18 - Norma: "Densa realidad" 19 - Juan Pablo Bochatón: "Tomo lo que encuentro"Radio Universidad Nacional de La Plat

Efficacy and safety of aficamten in symptomatic non-obstructive hypertrophic cardiomyopathy: results from the REDWOOD-HCM trial, cohort 4

Background This open-label phase 2 trial evaluated the safety and efficacy of aficamten in patients with nonobstructive hypertrophic cardiomyopathy (nHCM). Methods Patients with symptomatic nHCM (left ventricular outflow tract obstruction gradient ≤ 30 mmHg, left ventricular ejection fraction [LVEF] ≥ 60%, N-terminal pro-B-type natriuretic peptide [NT-proBNP] &gt; 300 pg/mL) received aficamten 5–15 mg once daily (doses adjusted according to echocardiographic LVEF) for 10 weeks. Results We enrolled 41 patients (mean ± SD age 56 ± 16 years; 59% female). At Week 10, 22 (55%) patients experienced an improvement of ≥ 1 New York Heart Association class; 11 (29%) became asymptomatic. Clinically relevant improvements in Kansas City Cardiomyopathy Questionnaire Clinical Summary Scores occurred in 22 (55%) patients. Symptom relief was paralleled by reductions in NT-proBNP levels (56%; P &lt; 0.001) and high-sensitivity cardiac troponin I (22%; P &lt; 0.005). Modest reductions in LVEF (mean ± SD) of −5.4% ± 10 to 64.6% ± 9.1 were observed. Three (8%) patients had asymptomatic reduction in LVEF &lt; 50% (range: 41%–48%), all returning to normal after 2 weeks of washout. One patient with prior history of aborted sudden cardiac death experienced a fatal arrhythmia during the study. Conclusions Aficamten administration for symptomatic nHCM was generally safe and was associated with improvements in heart failure symptoms and cardiac biomarkers

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.

Background Cardiac muscle hypercontractility is a key pathophysiological abnormality in hypertrophic cardiomyopathy, and a major determinant of dynamic left ventricular outflow tract (LVOT) obstruction. Available pharmacological options for hypertrophic cardiomyopathy are inadequate or poorly tolerated and are not disease-specific. We aimed to assess the efficacy and safety of mavacamten, a first-in-class cardiac myosin inhibitor, in symptomatic obstructive hypertrophic cardiomyopathy. Methods In this phase 3, randomised, double-blind, placebo-controlled trial (EXPLORER-HCM) in 68 clinical cardiovascular centres in 13 countries, patients with hypertrophic cardiomyopathy with an LVOT gradient of 50 mm Hg or greater and New York Heart Association (NYHA) class II–III symptoms were assigned (1:1) to receive mavacamten (starting at 5 mg) or placebo for 30 weeks. Visits for assessment of patient status occurred every 2–4 weeks. Serial evaluations included echocardiogram, electrocardiogram, and blood collection for laboratory tests and mavacamten plasma concentration. The primary endpoint was a 1·5 mL/kg per min or greater increase in peak oxygen consumption (pVO2) and at least one NYHA class reduction or a 3·0 mL/kg per min or greater pVO2 increase without NYHA class worsening. Secondary endpoints assessed changes in post-exercise LVOT gradient, pVO2, NYHA class, Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS), and Hypertrophic Cardiomyopathy Symptom Questionnaire Shortness-of-Breath subscore (HCMSQ-SoB). This study is registered with ClinicalTrials.gov, NCT03470545. Findings Between May 30, 2018, and July 12, 2019, 429 adults were assessed for eligibility, of whom 251 (59%) were enrolled and randomly assigned to mavacamten (n=123 [49%]) or placebo (n=128 [51%]). 45 (37%) of 123 patients on mavacamten versus 22 (17%) of 128 on placebo met the primary endpoint (difference +19·4%, 95% CI 8·7 to 30·1; p=0·0005). Patients on mavacamten had greater reductions than those on placebo in post-exercise LVOT gradient (−36 mm Hg, 95% CI −43·2 to −28·1; p<0·0001), greater increase in pVO2 (+1·4 mL/kg per min, 0·6 to 2·1; p=0·0006), and improved symptom scores (KCCQ-CSS +9·1, 5·5 to 12·7; HCMSQ-SoB −1·8, −2·4 to −1·2; p<0·0001). 34% more patients in the mavacamten group improved by at least one NYHA class (80 of 123 patients in the mavacamten group vs 40 of 128 patients in the placebo group; 95% CI 22·2 to 45·4; p<0·0001). Safety and tolerability were similar to placebo. Treatment-emergent adverse events were generally mild. One patient died by sudden death in the placebo group. Interpretation Treatment with mavacamten improved exercise capacity, LVOT obstruction, NYHA functional class, and health status in patients with obstructive hypertrophic cardiomyopathy. The results of this pivotal trial highlight the benefits of disease-specific treatment for this condition.pre-print482 K